share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  09/10 16:29

Moomoo AI 已提取核心信息

On September 6, 2024, Heart Test Laboratories, Inc., a Texas-based company, entered into a significant financial agreement with Streeterville Capital, LLC, an accredited investor. The agreement involved the issuance of an unsecured promissory note to Heart Test Laboratories for $2,510,000, which includes an original issue discount of $500,000 and $10,000 for transaction expenses. The note carries an 8.5% annual interest rate and is set to mature 18 months post-issuance. Streeterville has the option to redeem up to $270,000 per month starting six months after the note's issuance. If Heart Test Laboratories fails to reduce the note's outstanding balance by at least $900,000 by the 12-month anniversary, the balance will automatically increase by 5%. The company may prepay the balance at any time, subject to the agreement...Show More
On September 6, 2024, Heart Test Laboratories, Inc., a Texas-based company, entered into a significant financial agreement with Streeterville Capital, LLC, an accredited investor. The agreement involved the issuance of an unsecured promissory note to Heart Test Laboratories for $2,510,000, which includes an original issue discount of $500,000 and $10,000 for transaction expenses. The note carries an 8.5% annual interest rate and is set to mature 18 months post-issuance. Streeterville has the option to redeem up to $270,000 per month starting six months after the note's issuance. If Heart Test Laboratories fails to reduce the note's outstanding balance by at least $900,000 by the 12-month anniversary, the balance will automatically increase by 5%. The company may prepay the balance at any time, subject to the agreement's terms. The agreement also includes default provisions that could lead to an automatic increase in the outstanding balance to the lesser of 18% or the maximum rate permitted by law. Heart Test Laboratories has engaged Maxim Group LLC and Ascendiant Capital Markets, LLC as placement agents for the transaction, receiving a commission of 7% of the gross proceeds. The net cash proceeds, amounting to $1,860,000, are intended for general working capital purposes. The full details of the Note Purchase Agreement and the Streeterville Note are included in the company's filings with the SEC.
2024年9月6日,总部位于德克萨斯州的心脏检测实验室公司与Streeterville Capital有限责任公司,一家合格投资者,达成了一项重要的财务协议。该协议涉及发行给心脏检测实验室公司的一份无抵押票据,金额为251万美元,其中包括50万美元的原始发行贴现和1万美元的交易费用。该票据的年利率为8.5%,将在发行后的18个月到期。Streeterville有权在发行后的6个月起,每月赎回最多27万美元。如果心脏检测实验室公司未能在发行满一年的纪念日前将票据的未偿余额至少减少90万美元,该余额将自动增加5%。公司可以根据协议条款随时偿还余额。该协议还包括违约条款,可能导致未偿余额自动增加至不...展开全部
2024年9月6日,总部位于德克萨斯州的心脏检测实验室公司与Streeterville Capital有限责任公司,一家合格投资者,达成了一项重要的财务协议。该协议涉及发行给心脏检测实验室公司的一份无抵押票据,金额为251万美元,其中包括50万美元的原始发行贴现和1万美元的交易费用。该票据的年利率为8.5%,将在发行后的18个月到期。Streeterville有权在发行后的6个月起,每月赎回最多27万美元。如果心脏检测实验室公司未能在发行满一年的纪念日前将票据的未偿余额至少减少90万美元,该余额将自动增加5%。公司可以根据协议条款随时偿还余额。该协议还包括违约条款,可能导致未偿余额自动增加至不超过18%或法律允许的最高利率。心脏检测实验室公司已聘请Maxim Group LLC和Ascendiant Capital Markets LLC作为此次交易的承销商,并获得总票款的7%作为佣金。净现金收益186万美元,用于一般工作资金用途。完整的票据购买协议和Streeterville票据的详细信息已包含在公司提交给SEC的文件中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息